PlainPharmaWatch

CMS Open Payments · Program Year 2024

Lumenis BE inc

Lumenis BE inc reported $1,106,600.16 across General Payments, Research, and Ownership to 694 physicians and teaching hospitals across 694 transactions.

$1.1M
All-tracks total
694
Transactions
694
Recipients
−$25.0K
General Payments vs PY2023

Lumenis BE inc reported $1,106,600.16 across all CMS Open Payments tracks (General + Research + Ownership) to 694 physicians and teaching hospitals in Program Year 2024 - ranking #598 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,106,600.16, averaging $1.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer lumenis-be-inc Lumenis BE inc

$1.1M · #598/1,925 · 0.0% industry · PY2024

  • TOT $1.1M
  • RANK #598
  • SHARE 0.0%
  • TXN 694
  • RCP 694
  • CAT 2
  • GEN $1.1M
  • ΔGEN −$25.0K
  • TOP1 8.0%
  • PY 2024

Nearest volume peer: Neuronetics, Inc. ($1.1M)

Avid Radiopharmaceuticals, I…$1.1MLumenis BE inc (this)$1.1MNeuronetics, Inc.$1.1MKyowa Kirin Co., Ltd$1.1MCONMED Corporation$1.1M
All-tracks payment totals near Lumenis BE inc (CMS Open Payments PY2024)

Lumenis BE inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Lumenis BE inc's CMS-reported General Payments decreased by $25.0K (−2.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: LUMENIS BE INCPY2023: LUMENIS BE INCPY2024: Lumenis BE inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.1MPY2024$1.1M
PY2023
$1,131,581.29
PY2024
$1,106,600.16

What the Data Shows for Lumenis BE inc

Lumenis BE inc ranks #598 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $1,106,600.16 across 694 transactions to 694 physicians and teaching hospitals - $1.6K per transaction and $1.6K per recipient on average.

The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $1.0M, accounting for 90.6% of this company's General Payments and 666 transactions.

General Payment Breakdown by Type

"Food and Beverage" leads Lumenis BE inc's 2-category general-payment breakdown at $1.0M, 90.6% of the reported total.

How Lumenis BE inc divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$1.0M2. Compensation for Services…$103.5K
Payment Type Amount Transactions
Food and Beverage $1.0M 666
Compensation for Services Other Than Consulting $103.5K 28

Recipient Concentration in General Payments

The five largest recipient relationships account for $253,798.98 (22.9%) of $1,106,600.16 in this company's General Payments records across 432 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Lumenis BE inc

The five named recipients with the highest reported General Payments from this company

Nathan Lighthizer$88.0KShauna Diggs$54.9KRyan Gustus$40.1KJames Chelnis$37.8KRichard Adler$33.0K
  1. 1

    Nathan Lighthizer

    $88,000.00 across 4 reported transactions

  2. 2

    Shauna Diggs

    $54,897.27 across 11 reported transactions

  3. 3

    Ryan Gustus

    $40,075.26 across 4 reported transactions

  4. 4

    James Chelnis

    $37,826.45 across 12 reported transactions

  5. 5

    Richard Adler

    $33,000.00 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Lumenis BE inc's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Lumenis BE inc.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Lumenis BE inc.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Lumenis BE inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.